Vibha Jawa, executive director at Bristol Myers Squibb, discusses foreign epitopes recognition from what should be fully human antibody therapies.
Chris Spivey, editorial director, speaks with Vibha Jawa, executive director at Bristol Myers Squibb, on foreign epitopes recognition in what should be fully human antibody therapies. Can HLA genotyping show which binding targets will be most effective per individual patient, or per T cell response predictor in terms of a reverse translation in the clinic? A tangent from our upcoming conversation focused on High Titer Vector Producing Cells.
Ushering in Industry 4.0 with the IDMO Model to Solve the CGT Manufacturing Bottleneck
May 28th 2025Global scale-up requires developing replicable processes that work the same no matter where they are performed. This can be accomplished with smart factories that utilize fully automated manufacturing platforms.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.